Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Moderate Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $24.8750.

XNCR has been the subject of a number of recent research reports. Royal Bank Of Canada upped their target price on Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Monday, December 29th. Truist Financial initiated coverage on shares of Xencor in a report on Monday, November 24th. They set a “buy” rating and a $29.00 price objective for the company. Barclays lifted their target price on shares of Xencor from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Finally, Wedbush reissued an “outperform” rating and issued a $26.00 price target on shares of Xencor in a research report on Thursday, November 6th.

Xencor Stock Down 4.9%

Xencor stock opened at $11.62 on Friday. The business has a 50 day moving average price of $14.19 and a two-hundred day moving average price of $12.48. Xencor has a 12 month low of $6.92 and a 12 month high of $18.69. The stock has a market cap of $829.78 million, a price-to-earnings ratio of -6.56 and a beta of 0.98.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 73,367 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president owned 236,574 shares in the company, valued at $3,718,943.28. This trade represents a 23.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bassil I. Dahiyat sold 114,377 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $15.71, for a total value of $1,796,862.67. Following the completion of the sale, the chief executive officer owned 466,635 shares in the company, valued at $7,330,835.85. This trade represents a 19.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.76% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xencor

Several institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Xencor in the 4th quarter valued at about $296,000. MetLife Investment Management LLC grew its stake in shares of Xencor by 14.6% during the fourth quarter. MetLife Investment Management LLC now owns 40,212 shares of the biopharmaceutical company’s stock valued at $616,000 after purchasing an additional 5,122 shares during the last quarter. Alps Advisors Inc. increased its holdings in shares of Xencor by 72.3% in the fourth quarter. Alps Advisors Inc. now owns 58,639 shares of the biopharmaceutical company’s stock valued at $898,000 after purchasing an additional 24,606 shares in the last quarter. Swiss National Bank lifted its holdings in Xencor by 3.7% during the 4th quarter. Swiss National Bank now owns 119,600 shares of the biopharmaceutical company’s stock worth $1,831,000 after buying an additional 4,300 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Xencor by 378.8% in the 4th quarter. Deutsche Bank AG now owns 216,568 shares of the biopharmaceutical company’s stock valued at $3,316,000 after buying an additional 171,335 shares during the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.